PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)

The purpose of this study is to test whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing.

• Adult males 18+ years of age
• Confirmed progressive castration resistant prostate cancer
• Must have measurable disease
• No prior treatment with cabazitaxel plus carboplatin

• Submitting tumor tissue from a previous surgery or biopsy for genetic testing to look for changes in the DNA and RNA of your cancer
• Assignment to a treatment group based on the results of that genetic testing
• Study treatment based on your assigned group, which may include chemotherapy given through a vein (IV), hormone therapy taken by mouth, a targeted therapy called valemetostat tosylate, or a radioligand therapy given through a vein that delivers radiation directly to tumor cells
• Imaging with computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, bone scans, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, and fludeoxyglucose (FDG) positron emission tomography (PET) scans
• Sample collection for research, including blood samples during treatment
• Completing questionnaires about your symptoms and side effects